Okamura Homare, Emrich Fabian, Trojan Jeffrey, Chiu Peter, Dalal Alex R, Arakawa Mamoru, Sato Tetsuya, Penov Kiril, Koyano Tiffany, Pedroza Albert, Connolly Andrew J, Rabinovitch Marlene, Alvira Cristina, Fischbein Michael P
Department of Cardiothoracic Surgery, Stanford University, Stanford, California.
Department of Pathology, Stanford University, Stanford, California.
Physiol Rep. 2017 Apr;5(8). doi: 10.14814/phy2.13257. Epub 2017 Apr 28.
Aortic root aneurysm formation and subsequent dissection and/or rupture remain the leading cause of death in patients with Marfan syndrome. Our laboratory has reported that miR-29b participates in aortic root/ascending aorta extracellular matrix remodeling during early aneurysm formation in Marfan mice. Herein, we sought to determine whether miR-29b suppression can reduce aneurysm formation long-term. Marfan mice were treated with retro-orbital LNA-anti-miR-29b inhibitor or scrambled-control-miR before aneurysms develop either (1) a single dose prenatally (pregnant mice at 14.5 days post-coitum) ( = 8-10, each group) or (2) postnatally every other week, from 2 to 22 weeks of age, and sacrificed at 24 weeks ( = 8-10, each group). To determine if miR-29b blockade was beneficial even after aneurysms develop, a third group of animals were treated every other week, starting at 8 weeks of age, until sacrificed ( = 4-6, each group). miR-29b inhibition resulted in aneurysm reduction, increased elastogenesis, decreased matrix metalloproteinase activity and decreased elastin breakdown. Prenatal LNA-anti-miR-29b inhibitor treatment decreased aneurysm formation up to age 32 weeks, whereas postnatal treatment was effective up to 16 weeks. miR-29b blockade did not slow aortic growth once aneurysms already developed. Systemic miR-29b inhibition significantly reduces aneurysm development long-term in a Marfan mouse model. Drug administration during aortic wall embryologic development appears fundamental. miR-29b suppression could be a potential therapeutic target for reducing aneurysm formation in Marfan syndrome patients.
主动脉根部瘤形成以及随后的夹层分离和/或破裂仍然是马凡综合征患者的主要死亡原因。我们实验室报告称,miR-29b在马凡综合征小鼠早期动脉瘤形成过程中参与主动脉根部/升主动脉细胞外基质重塑。在此,我们试图确定抑制miR-29b是否能长期减少动脉瘤形成。在动脉瘤形成前,对马凡综合征小鼠进行眶后注射锁核酸抗miR-29b抑制剂或乱序对照miR处理,处理方式为:(1)产前单次给药(妊娠14.5天的孕鼠)(每组n = 8 - 10),或(2)出生后每隔一周给药,从2周龄至22周龄,并在24周龄时处死(每组n = 8 - 10)。为了确定即使在动脉瘤形成后阻断miR-29b是否有益,第三组动物从8周龄开始每隔一周给药,直至处死(每组n = 4 - 6)。抑制miR-29b可减少动脉瘤形成,增加弹性蛋白生成,降低基质金属蛋白酶活性,并减少弹性蛋白分解。产前锁核酸抗miR-29b抑制剂治疗可减少直至32周龄的动脉瘤形成,而产后治疗在16周龄前有效。一旦动脉瘤已经形成,阻断miR-29b并不会减缓主动脉生长。在马凡综合征小鼠模型中,全身性抑制miR-29b可长期显著减少动脉瘤发展。在主动脉壁胚胎发育期间给药似乎至关重要。抑制miR-29b可能是减少马凡综合征患者动脉瘤形成的潜在治疗靶点。